Actinium Pharmaceuticals, Inc., a biopharmaceutical company, announced that the official program of TAT: Target Alpha Therapy international symposium, in Oak Ridge, Tenn., will feature a presentation devoted to Actinium Pharmaceuticals' clinical programs. According to a release, the abstract entitled "Alpha-Particle Immunotherapy for Acute Myeloid.
AVEO Oncology and Astellas Pharma Inc. announced that additional data from the Phase 3 TIVO -1 trial of investigational agent tivozanib in patients with advanced renal cell carcinoma will be presented at the 2013 Annual Meeting of the American Society of Clinical Oncology taking place in Chicago, May 31- June 4. Date& Time: Monday, June 3, from 8 t
By a News Reporter-Staff News Editor at Obesity, Fitness& Wellness Week Aviir Inc., a biotechnology company dedicated to the prevention of cardiovascular disease through innovative laboratory tests, announced that it will be extending its offered services with comprehensive inherited cardiovascular disease genetic test menu. The newly validated t
-must apply to the US Food and Drug Administration for an "investigational new drug application". Human embryonic stem cells were turned into retinal pigment epithelial cells and then transplanted into his retina, as part of a trial by Advanced Cell Technology in Marlborough, Massachusetts. Russia's Bion-M1 spacecraft took a range of animals into o
May 24 In 2008, a local doctor flew to Florida for a meeting with ISTA Pharmaceuticals. The case, which dates back to 2007 and was under court-ordered seal in U.S. District Court until Friday, was based on allegations that ISTA improperly marketed one of its drugs, Xibrom, for medical uses not approved by the Food and Drug Administration. The FDA
Elan Corp., plc announced publication of a response document in respect of the Echo Pharma Acquisition Limited offer made on May 2. As previously advised, the Board of Elan has unanimously, and without reservation, rejected the offer by Royalty Pharma. A copy of the response document, which is being posted to Elan shareholders, is available online
By a News Reporter-Staff News Editor at Investment Weekly News Emergent BioSolutions Inc. announced that the company will be webcasting its presentation at the Bank of America Merrill Lynch 2013 Health Care Conference in Las Vegas on May 16, 2013 at 10:40 AM Pacific. About Emergent BioSolutions Inc. Emergent BioSolutions is a specialty pharmaceut
Wockhardt is the latest Indian drug maker to come under FDA fire. As Wockhardt comes under FDA fire, soon after Ranbaxy pleaded guilty to poor manufacturing practices and agreed to pay $500 million as penalty, the global repute of India's generic drug makers may have taken a hit. But even the "brand name companies" like GlaxoSmithKline, Boehringer
By a News Reporter-Staff News Editor at Investment Weekly News Pacira Pharmaceuticals, Inc. announced that James Scibetta, chief financial officer of Pacira Pharmaceuticals, is scheduled to present at the Bank of America Merrill Lynch 2013 Health Care Conference on Wednesday, May 15, 2013, at 5:00 p.m. PT at the Encore at the Wynn in Las Vegas.
By a News Reporter-Staff News Editor at Investment Weekly News- Questcor Pharmaceuticals, Inc. announced that executive management will present at the Bank of America Merrill Lynch 2013 Healthcare Conference in Las Vegas on May 14, 2013 at 4:20 PM PT/ 7:20 PM ET. Questcor Pharmaceuticals, Inc. is a biopharmaceutical company focused on the treatme
Relypsa, Inc., a biopharmaceutical company advancing lead product candidate, patiromer for the treatment of hyperkalemia, in a pivotal Phase 3 clinical study, announced the appointment of John Orwin as Chief Executive Officer of Relypsa. According to a release, Orwin brings over 20 years of diverse experience in the biotechnology and pharmaceutical
Actavis, Inc., a leading specialty pharmaceutical company, announced today that Paul Bisaro, Actavis' President and Chief Executive Officer, will provide an overview and update of the Company's business at the Sanford C. Bernstein Twenty-Ninth Annual Strategic Decisions Conference on Thursday, May 30, 2013 at 4:00 PM Eastern Time at the Waldorf Ast
In a letter to FDA Commissioner Margaret Hamburg, the senators urged the FDA to take all necessary steps to alleviate the shortage, especially as Lyme disease is most commonly contracted during May and June during peak tick season. The provisions require companies to give early warning notification to the FDA of any factor that may result in a drug
Adherex Technologies Inc., today announced that it has received feedback from the FDA at an End-of-Phase 2 meeting held yesterday. During the FDA meeting, Adherex reviewed the opportunity that eniluracil offers to Metastatic Breast Cancer patients who had rapid disease progression on capecitabine. Adherex proposed a small pivotal single arm clinica
CAMBRIDGE, Mass., May 24, 2013 Aegerion Pharmaceuticals, Inc., an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat debilitating and often fatal rare diseases, announced today that the company will participate in the Deutsche Bank 38th Annual Health Care Conference in Boston.
In a letter to FDA Commissioner Margaret Hamburg, the senators urged the FDA to take all necessary steps to alleviate the shortage, especially as Lyme Disease is most commonly contracted during May and June during peak tick season. The provisions require companies to give early warning notification to the FDA of any factor that may result in a drug
TOKYO& SAN FRANCISCO Astellas Pharma Inc. and Medivation, Inc. today announced that Astellas has submitted an application for marketing approval of enzalutamide to the Ministry of Health, Labour and Welfare in Japan for the treatment of prostate cancer. This filing application is based mainly on results obtained from the global Phase 3 trial* a
Auxilium Pharmaceuticals, Inc. today announced that executive management will participate in the Deutsche Bank Health Care Conference to be held May 29-30 at the Westin Boston Waterfront Hotel. About Auxilium Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a focus on developing and marketing products to predominantly...
CHI-California Healthcare Institute today submitted a letter to House Appropriators and the California congressional delegation, joined by over 40 biomedical companies, urging them to restore sequestered industry user fees paid to the U.S. Food and Drug Administration in 2013, and to ensure that future across-the-board cuts will not include user fe
Soricimed Biopharma Inc., a private clinical stage company developing novel cancer therapeutics and diagnostics, is pleased to announce that it has added a third site and first U.S. site, to its Phase I clinical trial, with the first patient beginning treatment this week with anti-cancer agent SOR-C13 at The University of Texas MD Anderson Cancer C
May 24 In 2008, a local doctor flew to Florida for a meeting with ISTA Pharmaceuticals. The case, which dates back to 2007 and was under court-ordered seal in U.S. District Court until Friday, was based on allegations that ISTA improperly marketed one of its drugs, Xibrom, for medical uses not approved by the Food and Drug Administration. The FDA
Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced today excellent long-term results of its CE Mark-approved DESyne BD Novolimus Eluting Coronary Stent System with biodegradable polymer coating compared to the control Endeavor Zotarolimus Eluting...
By a News Reporter-Staff News Editor at Health& Medicine Week Masimo announced that its rainbow Acoustic Monitoring? sensor, RAS-125c Acoustic Respiration Cloth Sensor has received U.S. FDA 510 clearance for continuous, noninvasive monitoring of acoustic respiration rate in pediatric patients. Masimo rainbow Acoustic Monitoring noninvasively an
Dublin- Research and Markets has announced the addition of the " Generic Pharmaceuticals" report to their offering. Despite the Global Generic Pharmaceutical industry becoming increasingly competitive there are 42 vibrant companies across the World exploiting innovative, more profitable routes to market. Just published the Plimsoll Global Analysis-
The Icahn School of Medicine at Mount Sinai has granted Cellular Dynamics International exclusive license rights to commercially develop cardiomyocyte progenitors for in vivo cell therapy and regenerative medicine applications. The licensed technology is based on research first conducted by Gordon Keller, PhD, a former Professor of Gene and Cell...
